LEADER 00971cam0-2200289---450 001 990009719500403321 005 20200313082216.0 010 $a978-88-425-4377-0 100 $a20130419d2011----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa-------001yy 200 1 $aDalle navi bianche alla linea gotica$e1941-1944$fMassimo Zamorani$gprefazione di Mario Cervi 210 $aMilano$cMursia$d2011 215 $a217 p.$c[5] carte di tav. : ill.$d21 cm 225 1 $aTestimonianze fra cronaca e storia$i1939-1945: seconda guerra mondiale 610 0 $aGuerra mondiale 1939-1945$aAfrica orientale$a1941-1944$aDiari e memorie 676 $a940.548245$v22$zita 700 1$aZamorani,$bMassimo$0519826 702 1$aCervi,$bMario 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a990009719500403321 952 $aXIV B 2021$b48726$fFSPBC 959 $aFSPBC 996 $aDalle navi bianche alla linea gotica$9842106 997 $aUNINA LEADER 03579nam 2200637Ia 450 001 9911019280003321 005 20200520144314.0 010 $a9786611840525 010 $a9781281840523 010 $a1281840521 010 $a9780470697405 010 $a0470697407 010 $a9780470697412 010 $a0470697415 035 $a(CKB)1000000000551489 035 $a(EBL)366846 035 $a(SSID)ssj0000136162 035 $a(PQKBManifestationID)11150469 035 $a(PQKBTitleCode)TC0000136162 035 $a(PQKBWorkID)10064010 035 $a(PQKB)11282680 035 $a(MiAaPQ)EBC366846 035 $a(OCoLC)264703263 035 $a(Perlego)2757182 035 $a(EXLCZ)991000000000551489 100 $a20080305d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDefining optimal immunotherapies for type 1 diabetes /$f[editors: Gregory Bock and Jamie Goode] 210 $aLondon $cNovartis Foundation$d2008 215 $a1 online resource (224 p.) 225 1 $aNovartis Foundation symposium ;$vv. 292 300 $aDescription based upon print version of record. 311 08$a9780470723258 311 08$a0470723254 320 $aIncludes bibliographical references and index. 327 $aDefining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes 327 $aCD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index 330 $aThis book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.The book integrates information from human and animal studies.The book considers T1D within the broader context of autoimmune disease.The format contains several discussions, which address specific questions and provides 410 0$aNovartis Foundation symposium ;$vv. 292. 606 $aDiabetes$xImmunotherapy$vCongresses 606 $aDiabetes$xTreatment$vCongresses 615 0$aDiabetes$xImmunotherapy 615 0$aDiabetes$xTreatment 676 $a616.46206 712 02$aNovartis Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911019280003321 996 $aDefining optimal immunotherapies for type 1 diabetes$93068900 997 $aUNINA